Can a new drug combo reset the immune system to beat relapsed leukemia?
NCT ID NCT07757672
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial tests whether a combination of sonrotoclax, cladribine, and cytarabine, followed by a stem cell transplant, can improve survival in adults with relapsed or refractory acute myeloid leukemia (AML). Participants receive the chemotherapy regimen, then undergo an allogeneic stem cell transplant within weeks, and may continue sonrotoclax as maintenance. The study aims to see if this strategy improves 2-year survival and reduces relapse, while monitoring safety and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of sonrotoclax, cladribine, and cytarabine, followed by an allogeneic stem cell transplant
- What this could lead to
- If successful, this approach could offer a path to long-term remission or even a cure for people with hard-to-treat AML.
- What could go wrong
- This is an early-phase, single-arm trial with no comparison group, so results may not be definitive. The chemotherapy and transplant carry significant risks, including infection and treatment-related mortality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can umbilical cord blood keep leukemia at bay in older patients?
- New study aims to predict hidden hepatitis b danger in transplant patients
- New chemo cocktail aims to boost stem cell transplant success in leukemia
- New blood test may predict cancer relapse after transplant
- Fitness check may guide better leukemia care for seniors
- New trial aims to match AML patients with best drug combo